Skip to Main content Skip to Navigation
Journal articles

FDG-PET/CT in Lymphoma: Where Do We Go Now?

Abstract : 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is an essential part of the management of patients with lymphoma at staging and response evaluation. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma but also points out the potential place of innovative PET/CT metrics or new radiopharmaceuticals in the future.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03540811
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Monday, January 24, 2022 - 11:29:56 AM
Last modification on : Wednesday, June 1, 2022 - 3:58:33 AM
Long-term archiving on: : Monday, April 25, 2022 - 6:46:04 PM

File

cancers-13-05222-v2.pdf
Publisher files allowed on an open archive

Identifiers

Citation

yassine Al Tabaa, Clement Bailly, Salim Kanoun. FDG-PET/CT in Lymphoma: Where Do We Go Now?. Cancers, MDPI, 2021, 13 (20), pp.5222. ⟨10.3390/cancers13205222⟩. ⟨inserm-03540811⟩

Share

Metrics

Record views

14

Files downloads

20